Document is current
Any future updates will be listed below
-
Authors
Xiong, Mengshang
Kong, Chunfang
Lu, Yang
Liu, Jiaojun
Ding, Weirong
Zhang, Tingting
Zuo, Wei
Cao, Lixia
Lu, Qiling
Li, Anna
Li, Chaoyu
Ding, Liting
Yan, Yutao
Ke, Bo
Wan, Caishui https://orcid.org/0009-0002-6653-3232
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (NO. 82400238)
Jiangxi Provincial Natural Science Foundation (No. 20224BAB216062)
Jiangxi Provincial Health Technology Project (No. 202410140)
CAMS Innovation Fund for Medical Sciences (CIFMS：2021-I2M-1-041)
- License Information
-
More Information
Article History
Received: 3 December 2024
Accepted: 30 January 2025
First Online: 12 February 2025
Declarations
:
: All animal experiments received approval from the ethical committee of Nanchang Medical College (Project title: Human mesenchymal stem cells as vehicles of tetravalent bispecific Tandab for the treatment of multiple myeloma combined with gamma-secretase inhibitors and its mechanism study; Approval number: NYLLSC20240701; Date of approval: 01/07/2024). Human MSCs, PBMC, and CD138+ BMMNCs were respectively isolated from umbilical cord, peripheral blood, and bone marrow with informed patient consent in accordance with the ethical committee of Jiangxi Provincial People’s Hospital (Project title: Human mesenchymal stem cells as vehicles of tetravalent bispecific Tandab for the treatment of multiple myeloma combined with gamma-secretase inhibitors and its mechanism study; Approval number: 2024 (81); Date of approval: 11/11/2024).
: Not applicable.
: The authors declare that they have no competing interests.
